Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cyclodextrins.

Valentino J Stella1, Quanren He

  • 1Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, Kansas 66047, USA. stella@ku.edu

Toxicologic Pathology
|March 14, 2008
PubMed
Summary
This summary is machine-generated.

Sulfobutyl ether beta-cyclodextrin (SBE-beta-CD) and hydroxypropyl beta-cyclodextrin (HP-beta-CD) offer improved drug delivery and safety. These cyclodextrin derivatives demonstrate excellent drug solubilization, stability, and bioavailability with no observed adverse effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immunogenicity, Efficacy and Twelve-Month Storage Stability Studies of a Lyophilized Rabies mRNA Vaccine.

Vaccines·2025
Same author

Bortezomib Aqueous Solubility in the Presence and Absence of D-Mannitol: A Clarification With Formulation Implications.

Journal of pharmaceutical sciences·2020
Same author

Prodrugs: My Initial Exploration and Where It Led.

Journal of pharmaceutical sciences·2020
Same author

Sulfobutylether-β-cyclodextrin.

International journal of pharmaceutics·2020
Same author

Boric Acid, a Lewis Acid With Unique and Unusual Properties: Formulation Implications.

Journal of pharmaceutical sciences·2020
Same author

Some Preformulation Studies of Pyruvic Acid and Other α-Keto Carboxylic Acids in Aqueous Solution: Pharmaceutical Formulation Implications for These Peroxide Scavengers.

Journal of pharmaceutical sciences·2019
Same journal

Comparison of Standard Clinical Pathology Parameter Values in Fasted and Fed Rats and Non-human Primates.

Toxicologic pathology·2026
Same journal

Time-Dependent Autolysis in Ex Vivo-Maintained Rat Tissue in Saline: A Descriptive Study and Practical Guidance for Histopathologic Assessment.

Toxicologic pathology·2026
Same journal

New Approach Methodologies (NAMs) for Carcinogenicity Evaluation.

Toxicologic pathology·2026
Same journal

2025 International Academy of Toxicologic Pathology (IATP) Satellite Symposium: Pathology Working Groups (PWGs) in Toxicologic Pathology.

Toxicologic pathology·2026
Same journal

Toxicologic Pathology Forum*: Opportunities and Challenges in the Use of Artificial Intelligence in Nonclinical Toxicologic Histopathology Evaluations.

Toxicologic pathology·2026
Same journal

New Modalities and Carcinogenicity Assessment.

Toxicologic pathology·2026
See all related articles

Area of Science:

  • Pharmaceutical Sciences
  • Drug Delivery
  • Biomedical Engineering

Background:

  • Traditional cyclodextrins (CDs) can be nephrotoxic for parenteral administration.
  • Development of safer, more effective CD derivatives is crucial for drug formulation.
  • Need for improved drug solubility, stability, and bioavailability drives innovation in CD technology.

Purpose of the Study:

  • To review the development, safety, characterization, and applications of SBE-beta-CD (Captisol) and HP-beta-CD.
  • To highlight their role in enhancing drug delivery, particularly for poorly soluble drugs.
  • To assess the safety profiles and human tolerability of these advanced cyclodextrin derivatives.

Main Methods:

  • Review of existing literature on SBE-beta-CD and HP-beta-CD.

Related Experiment Videos

  • Analysis of safety studies, including pharmacokinetic and tissue distribution data.
  • Evaluation of clinical and preclinical data on drug complexation and therapeutic outcomes.

    • Main Results:

    • SBE-beta-CD and HP-beta-CD are non-nephrotoxic and approved in multiple FDA-marketed products.
    • These derivatives enhance drug solubility, stability, and oral bioavailability.
    • Complexes show rapid dissociation in vivo, with no tissue irritation and good tolerability in humans.

    Conclusions:

    • SBE-beta-CD and HP-beta-CD represent significant advancements in cyclodextrin-based drug delivery.
    • Their favorable safety profiles and efficacy make them valuable excipients for pharmaceutical development.
    • These derivatives offer a promising solution for overcoming challenges in formulating poorly water-soluble drugs.